Business Context and Reporting Period
Company: Bristol-Myers Squibb Company
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2002
Context: The company is navigating a significant workdown of U.S. wholesaler inventory levels that built up in 2000 and 2001 due to sales incentives. This period also reflects the integration of the DuPont Pharmaceuticals acquisition (completed Oct 2001) and ongoing litigation regarding patent enforcement and pricing practices.
Key Financial Metrics
| Metric (Millions) | Q2 2002 | Q2 2001 | 6M 2002 | 6M 2001 |
|---|---|---|---|---|
| Net Sales | $4,053 | $4,709 | $8,135 | $9,398 |
| Net Earnings | $440 | $1,201 | $1,025 | $2,537 |
| Diluted EPS | $0.23 | $0.61 | $0.53 | $1.29 |
| Operating Cash Flow | N/A | N/A | ($680) | $2,383 |
| Cash & Equivalents | $3,547 | N/A | $3,547 | N/A |
| Total Debt (Short + Long) | $6,925 | N/A | $6,925 | N/A |
| Working Capital | $3,188 | N/A | $3,188 | N/A |
Note: Q2 Operating Cash Flow is not explicitly provided in the text; only the six-month figure is available.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 14% in Q2 and 13% for the six months ended June 30, 2002, compared to 2001. Domestic sales fell 23% due to the wholesaler inventory workdown and generic competition for key products (GLUCOPHAGE IR, TAXOL, BUSPAR).
- Profitability Drop: Net earnings from continuing operations fell 60% in Q2 and 56% for the six-month period. Earnings before taxes dropped from $1,501 million to $597 million in Q2.
- Cash Flow Reversal: Operating cash flow swung from a positive $2,383 million in the first six months of 2001 to a negative $680 million in 2002. This was primarily driven by $1,755 million in income tax payments (related to the Clairol divestiture gain) and lower net earnings.
- Debt Structure: Short-term borrowings increased to $785 million from $174 million at year-end 2001, largely due to commercial paper issuance. Long-term debt remained relatively stable at $6.14 billion.
- Non-Recurring Items: The six-month period included a $262 million reduction in earnings due to a Medicaid/prime vendor rebate accrual adjustment, a $125 million litigation charge, and a $112 million in-process R&D charge related to ImClone.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Inventory Workdown: Management estimates the total earnings per share impact of the wholesaler inventory workdown will be approximately $0.61 per diluted share. Nearly half of this impact was realized in the first half of 2002. The workdown is expected to extend through the full year 2003, longer than previously anticipated, due to non-exclusive products (GLUCOPHAGE IR, BUSPAR, MEGACE O/S).
- Product Pipeline: The FDA Advisory Committee recommended against the approval of VANLEV (omapatrilat) in July 2002. A Marketing Authorization Application for atazanavir (HIV/AIDS) was submitted to the European Medicines Evaluation Agency.
- Segment Performance: International pharmaceutical sales grew 6% (8% excluding FX), driven by PRAVACHOL and DuPont products. Nutritionals sales increased 11% in Q2.
Risks and Contingencies
- Litigation: Significant pending litigation includes:
- TAXOL: Patent infringement suits and antitrust counterclaims; generic competition has begun.
- BUSPAR: Antitrust suits and patent validity challenges; courts have allowed antitrust claims to proceed.
- AWP Litigation: Class actions alleging false Average Wholesale Price reporting.
- Securities Matters: Class actions regarding VANLEV safety data, wholesaler inventory incentives, and the ImClone investment. The SEC has initiated an inquiry into the wholesaler inventory situation.
- ImClone Investment: The carrying value of the ImClone investment ($486 million) significantly exceeds the market price ($8.69/share vs. $33.75 carrying value). A write-down may be required if the decline is deemed not temporary.
- Generic Competition: Loss of exclusivity for GLUCOPHAGE IR, TAXOL, and BUSPAR continues to erode domestic sales.
Investor Verification Checklist
- Inventory Workdown Timeline: Verify the progress of reducing U.S. wholesaler inventory levels and the accuracy of the $0.61 EPS impact estimate.
- ImClone Valuation: Monitor the market price of ImClone Systems relative to Bristol-Myers Squibb's carrying value to assess potential impairment charges.
- Litigation Outcomes: Track developments in the BUSPAR antitrust cases and the SEC inquiry regarding wholesaler inventory accounting.
- Product Pipeline: Confirm the final FDA decision on VANLEV and the status of the atazanavir application in Europe.
- Cash Flow Sustainability: Assess the company's ability to maintain liquidity given the negative operating cash flow in the first half of 2002 and high tax payments.